OBI Researchers Develop Novel Serum for Cancer Therapy

Our Blood Institute (OBI), an AABB institutional member based in Oklahoma, recently announced the development of a first-of-its-kind serum that utilizes donor plasma as part of a stimulus needed for the expansion of manipulated white blood cells programmed to fight specific cancers. Only plasma volunteered to OBI’s research team was used for the development of the serum.

“OBI has always been on the cutting edge of transfusion medicine. As medical treatments have progressed, we now need to be innovative and lead with cell-based cancer therapy solutions,” said Charles Mooney, OBI’s vice president of Research and Biodevelopment. “As we entered this new field of medicine, we quickly saw there were problems we could use our knowledge and experience to resolve.”